Literature DB >> 29308710

Medication adherence and adverse effect profile of antiepileptic drugs in Nigerian patients with epilepsy.

Joseph O Fadare1, Taofiki A Sunmonu2, Idowu A Bankole3, Kehinde A Adekeye4, Sani A Abubakar5.   

Abstract

AIM: Medication adherence remains a major challenge among patients with epilepsy (PWE) with the adverse effect profile of antiepileptic drugs (AEDs) as one of its main drivers.
METHODS: This was a cross-sectional questionnaire-based study among PWE in selected Nigerian tertiary healthcare facilities using the Morisky Medication Adherence Scale and the Liverpool Adverse Effect Profile (LAEP).
RESULTS: 126 PWE from four tertiary healthcare facilities were included in this study comprising of 59 (46.8%) males and 67 (53.2%) females. Carbamazepine (104/70.7%), sodium valproate (23/15.6%) and phenytoin (11/7.5%) were the most commonly prescribed AEDs. Using the Morisky Medication Adherence Scale, 17.2, 38.3 and 44.5% of patients were classified as having high, medium and low adherence, respectively. The mean LAEP score was 23.69 ± 6.07. The most common reported adverse effects among respondents were tiredness (30.4%) and headache (22.5%).
CONCLUSION: Medication adherence to AED was poor among patients in this study.

Entities:  

Keywords:  Liverpool Adverse Effect Profile score; adverse drug reactions; antiepileptic drugs; epilepsy treatment; medication adherence

Mesh:

Substances:

Year:  2018        PMID: 29308710     DOI: 10.2217/nmt-2017-0044

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  2 in total

1.  A retrospective study of Ganoderma Lucidum Spore Powder for patients with epilepsy.

Authors:  Guo-Hui Wang; Xin Li; Wen-Hui Cao; Jing Li; Li-Hua Wang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

2.  Adherence to Antiepileptic Drugs among Patients Attending the Neuro Spinal Hospital in the United Arab Emirates.

Authors:  Enas S Abd Wahab; Muaed Al Omar; Moawia M A M Altabakha
Journal:  J Pharm Bioallied Sci       Date:  2020-10-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.